Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Peritonitis D010538 38 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Epilepsy D004827 35 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Burns D002056 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Uremia D014511 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Stroke D020521 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Proteinuria D011507 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Neuralgia D009437 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Gastritis D005756 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Madi S et al. Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. 1991 Agents Actions pmid:2058463
Braquet P and Esanu A New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. 1991 Agents Actions pmid:2058466
Desai S and Barton R Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. 1990 Agents Actions pmid:2285021
Howat DW et al. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. 1989 Agents Actions pmid:2801340
Appleby P and Bowen JG Cutaneous inflammatory disorders. 1990 Agents Actions pmid:2117335
Lundgren JD et al. Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway. 1990 Agents Actions pmid:2117336
Doyle SA et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. 1990 Agents Actions pmid:2178317
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Adnot S et al. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. 1987 Agents Actions pmid:3115070
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Morley J Platelet activating factor and asthma. 1986 Agents Actions pmid:3099555
Cahill M et al. Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. 1988 Agents Actions pmid:3051930
Friedlander G et al. Renal effects of platelet-activating factor in the rat. 1987 Agents Actions pmid:3687594
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Lauri D et al. Contribution of ADP to the amplification of primary platelet aggregation by platelet activating factor (PAF): modulatory role of aspirin. 1986 Agents Actions pmid:3706054
Etienne A et al. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. 1986 Agents Actions pmid:3515870
Pettipher ER et al. PAF-acether in chronic arthritis. 1987 Agents Actions pmid:3630862
Archer CB et al. Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether. 1985 Agents Actions pmid:3923788
Parente L et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. 1986 Agents Actions pmid:3962774
Tarayre JP et al. Inflammatory action of PAF-acether in the rat pleural cavity. 1986 Agents Actions pmid:3962789
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Boughton-Smith NK et al. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. 1992 Agents Actions pmid:1279960
Rachmilewitz D et al. Cytokines and platelet-activating factor in human inflamed colonic mucosa. 1992 Agents Actions pmid:1359744
Ogunbiyi PO and Eyre P Pharmacological studies of pulmonary anaphylaxis in vitro: a review. 1985 Agents Actions pmid:2420161
Canale P et al. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994 Agents Actions pmid:7879698
Sakamoto T et al. Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. 1993 Agents Actions pmid:7908496
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
Mencia-Huerta JM et al. Is platelet-activating factor (PAF-acether) synthesis by murine peritoneal cells (PC) a two-step process? 1981 Agents Actions pmid:7053072
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Convert O et al. 1H NMR of PAF-acether: influence of solvent on its structure. 1982 Agents Actions pmid:7164943
Borrel MC et al. Additional techniques for the total synthesis of PAF-acether. 1982 Agents Actions pmid:7164944
Benveniste J et al. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. 1982 Agents Actions pmid:7164945
Arnoux B et al. Release of PAF-acether from human blood monocytes. 1982 Agents Actions pmid:7164946
Fouque F et al. Platelet-activating factor (PAF-acether): thromboxane-independent synergism with adrenaline on human platelets and recent insights into its mode of action. 1982 Agents Actions pmid:7164947
Lefort J et al. Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. 1982 Agents Actions pmid:7164948
Bonnet J et al. Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. 1981 Agents Actions pmid:7340441
Denjean A et al. Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. 1981 Agents Actions pmid:7340444
Louis R et al. Potentiation of histamine release from human leucocytes by PAF. 1994 Agents Actions pmid:7521570
Izzo AA et al. Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents. 1994 Agents Actions pmid:7524288
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kelefiotis D and Vakirtzi-Lemonias C In vivo responses of mouse blood cells to platelet-activating factor (PAF): role of the mediators of anaphylaxis. 1993 Agents Actions pmid:8023738
Northover AM and Northover BJ Involvement of protein kinase C in the control of microvascular permeability to colloidal carbon. 1993 Agents Actions pmid:8304240
Etienne A et al. Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. 1986 Agents Actions Suppl. pmid:3468781
Anderson GP and Fennessy MR Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. 1988 Agents Actions Suppl. pmid:3140616
Bertrand C et al. Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. 1990 Agents Actions Suppl. pmid:2080755